Purpose. To evaluate gel microstent (XEN, Aquesys, Inc) for treatment of primary open angle glaucoma (POAG). Methods. In this\nprospective interventional study, 13 eyes with POAG underwent XEN implantation with subconjunctival mitomycin-C. Of those\neyes, 3 were pseudophakic and 10 underwent simultaneous phacoemulsification and XEN. Patients had uncontrolled IOP, had\nintolerance to therapy, or had maximal therapy but undergoing cataract extraction. Follow-up visits included IOP, number of\nmedications, vision, and complications and lasted for 1 year. Complete success was defined as IOP reduction â�¥20% from\npreoperative baseline at 1 year without any glaucoma medications while partial success as IOP reduction of â�¥20% at 1 year with\nmedications. Results. IOP dropped from 16 �± 4mmHg pre-op to 9 �± 5, 11 �± 6, 12 �± 5, 12 �± 4, and 12 �± 3mmHg at 1 week, 1, 3, 6,\nand 12 months (p = 0 004, 0.026, 0.034, 0.01, and 0.01, Wilcoxon Signed Ranks) consecutively. BCVA (LogMAR) was 0.33 �± 0.34\nand improved to 0.13 �± 0.11 at 1 year. Mean number of medications dropped from 1.9 �± 1 preoperatively to 0.3 �± 0.49 (p = 0 003)\nat 1 year. 42% of eyes achieved complete success and 66% qualified success. Complications included choroidal detachment\nin 2 eyes, and implant extrusion in 1 eye, and 2 eyes underwent trabeculectomy. Conclusion. XEN implant is an effective surgical\ntreatment for POAG, with significant reduction in IOP and glaucoma medications at 1 year follow-up.
Loading....